Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.

Jonathan R S Arch1

  • 1GlaxoSmithKline, New Fontiers Science Park-North, Coldharbour Road, Harlow, Essex CM19 5AD, UK. jon.arch@buckingham.ac.uk

European Journal of Pharmacology
|May 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic administration of hydrolysed pine nut oil to mice improves insulin sensitivity and glucose tolerance and increases energy expenditure via a free fatty acid receptor 4-dependent mechanism.

The British journal of nutrition·2024
Same author

Leanness and Low Plasma Leptin in GPR17 Knockout Mice Are Dependent on Strain and Associated With Increased Energy Intake That Is Not Suppressed by Exogenous Leptin.

Frontiers in endocrinology·2021
Same author

High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.

PeerJ·2020
Same author

Developmental programming of appetite and growth in male rats increases hypothalamic serotonin (5-HT)5A receptor expression and sensitivity.

International journal of obesity (2005)·2020
Same author

Is energy expenditure reduced in obese mice with mutations in the leptin/leptin receptor genes?

Journal of nutritional science·2020
Same author

Preventive effects of <i>Salvia officinalis</i> leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone.

PeerJ·2018
Same journal

Baicalin downregulates Thromboxane A<sub>2</sub> receptor via SIRT1/NRF2 and NLRP3 pathways to attenuate Cyclosporine A-induced hypertension.

European journal of pharmacology·2026
Same journal

ARBUTIN AS A THERAPEUTIC CANDIDATE FOR AUTISM: CURRENT EVIDENCE AND MECHANISTIC INSIGHTS INTO PI3K/Akt/mTOR and Nrf2 PATHWAYS.

European journal of pharmacology·2026
Same journal

Repeated Ethanol Exposure in Female Rats Impairs Cerebral Endothelial Function and Increases Cerebrovascular Stiffness.

European journal of pharmacology·2026
Same journal

Valerenic acid attenuates chronic stress-exacerbated metabolic dysfunction-associated steatotic liver disease via the estrogen receptor α-GDF15 axis.

European journal of pharmacology·2026
Same journal

Theranekron Prevents Endotoxin-Induced Acute Kidney Injury by Modulating Inflammatory and Mitochondrial Apoptotic Pathways.

European journal of pharmacology·2026
Same journal

Icariside Ⅱ alleviates heart failure based on Wnt/β-catenin-mitochondrial apoptotic pathway.

European journal of pharmacology·2026
See all related articles

Beta(3)-adrenoceptor agonists promote thermogenesis and improve insulin sensitivity in rodents. While less abundant in humans, these receptors in adipose tissue and muscle still influence energy balance and glucose homeostasis.

Area of Science:

  • Pharmacology
  • Metabolism
  • Endocrinology

Background:

  • Beta(3)-adrenoceptor agonists are effective thermogenic and insulin-sensitizing agents in rodents, primarily acting on adipose tissue and muscle.
  • Human adipose tissue has lower Beta(3)-adrenoceptor mRNA levels and less brown adipose tissue compared to rodents.
  • Despite differences, Beta(3)-adrenoceptors are present in human white and brown adipose tissue and skeletal muscle, impacting energy balance and glucose homeostasis.

Purpose of the Study:

  • To investigate the role and therapeutic potential of Beta(3)-adrenoceptor agonists in humans.
  • To understand the challenges in developing selective Beta(3)-adrenoceptor agonists due to pharmacological variations and bioavailability issues.
  • To explore the mechanisms behind the rapid insulin-sensitizing effects of Beta(3)-adrenoceptor agonists.

Related Experiment Videos

Main Methods:

  • Review of existing literature on Beta(3)-adrenoceptor pharmacology and function in rodents and humans.
  • Analysis of Beta(3)-adrenoceptor expression levels in human tissues.
  • Pharmacological characterization of Beta(3)-adrenoceptor agonists, focusing on selectivity and bioavailability.

Main Results:

  • Beta(3)-adrenoceptors are expressed in human white and brown adipose tissue and skeletal muscle, influencing energy and glucose metabolism.
  • Developing selective Beta(3)-adrenoceptor agonists is challenging due to potential cross-reactivity with Beta(1/2)-adrenoceptors and poor oral bioavailability.
  • Beta(3)-adrenoceptor agonists demonstrate a faster insulin-sensitizing effect than anti-obesity effects, potentially by reducing lipid metabolites that inhibit insulin signaling.

Conclusions:

  • Beta(3)-adrenoceptors remain a viable target for modulating energy balance and glucose homeostasis in humans, despite lower expression levels.
  • Overcoming selectivity and bioavailability challenges is crucial for the clinical development of Beta(3)-adrenoceptor agonists.
  • The rapid insulin-sensitizing action suggests a significant role in improving glucose metabolism, possibly through modulation of protein kinase C pathways.